Contact
      Please use this form to send email to PR contact of this press release:
      
      Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
    
      TO: